‘Unprecedented’ Sales for Merck’s Gardasil Vaccine as They Seek World Domination for HPV Vaccines
Merck's Gardasil vaccine saw a 55% increase over last year’s third quarter, netting $1.05 billion in global sales for the third quarter of 2018. Thanks to worldwide sales, the Gardasil vaccine has become the top money maker for Merck. FiercePharma, the marketing trade publication for vaccine manufacturers, reports that Merck’s Gardasil has been propelling the pharma giant’s vaccine unit in recent quarters, and that doesn't look like it'll be changing. The company sees more growth ahead thanks to an “unprecedented increase in worldwide demand” for HPV vaccines, an executive said. Addressing the vaccine's performance on a recent conference call, Merck’s president of global human health Adam Schechter said the company is “seeing unprecedented increase in worldwide demand for the HPV vaccines.” He said global demand has “doubled in the last year alone.” Meanwhile, the carnage left behind from mass Gardasil vaccination programs continues to get world-wide exposure, as doctors, scientists, and victims look for ways to oppose mass Gardasil vaccination programs. A recent gathering in Ireland at an IFICA conference brought together many world leaders to discuss the Gardasil problem, and another meeting is scheduled in the U.S. in 2019 during the Autism One conference, at the 4th Annual International HPV Vaccine Education Symposium.